Literature DB >> 7028577

Abnormalities of neutrophil function do not cause the migration defect in Crohn's disease.

C O Moráin, A A Segal, D Walker, A J Levi.   

Abstract

Skin window tests were performed on 60 patients with Crohn's disease, 20 with ulcerative colitis, 16 with peptic ulceration, and 40 healthy controls. The numbers of neutrophils that migrated into the skin window chambers were significantly lower in patients with Crohn's disease. This abnormality was unrelated to the activity of the disease, site of involvement, or treatment. No significant abnormalities were found in the patients with other diseases of the gastrointestinal tract. The abnormality of neutrophil migration in the Crohn's patients does not seem to be due to a cellular defect, as neutrophils from patients with Crohn's disease migrate and phagocytose normally in vitro. Sera from patients with Crohn's disease did not inhibit cell migration or contain inhibitors of chemotaxis. The addition of serum that had been activated with zymosan to the chamber enhanced the emigration of neutrophils from the skin of patients with Crohn's disease. These results suggest that the depression of neutrophil migration into skin windows that is normally observed in Crohn's disease is due to a deficient local inflammatory response. This defective inflammatory response in Crohn's disease and the consequent delay in the accumulation of neutrophils could explain granuloma formation, the high recurrence rate after surgery, and the clinical course of exacerbations and remissions.

Entities:  

Mesh:

Year:  1981        PMID: 7028577      PMCID: PMC1419419          DOI: 10.1136/gut.22.10.817

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator.

Authors:  P A Ward; J L Berenberg
Journal:  N Engl J Med       Date:  1974-01-10       Impact factor: 91.245

2.  Gastrointestinal manifestations of chronic granulomatous disease.

Authors:  M E Ament; H D Ochs
Journal:  N Engl J Med       Date:  1973-02-22       Impact factor: 91.245

3.  Kinetics of oxygen consumption by phagocytosing human neutrophils.

Authors:  A W Segal; S B Coade
Journal:  Biochem Biophys Res Commun       Date:  1978-10-16       Impact factor: 3.575

4.  Distinct chemokinetic and chemotactic responses in neutrophil granulocytes.

Authors:  H U Keller; J H Wissler; M W Hess; H Cottier
Journal:  Eur J Immunol       Date:  1978-01       Impact factor: 5.532

5.  An inherited defect of neutrophil mobility in Shwachman syndrome.

Authors:  P J Aggett; J T Harries; B A Harvey; J F Soothill
Journal:  J Pediatr       Date:  1979-03       Impact factor: 4.406

6.  Neutrophil dysfunction in Crohn's disease.

Authors:  A W Segal; G Loewi
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

7.  Defective regulation of chemotaxis in cirrhosis.

Authors:  E C Maderazo; P A Ward; R Quintiliani
Journal:  J Lab Clin Med       Date:  1975-04

8.  Inhibition of neutrophil migration by sera from patients with rheumatoid arthritis.

Authors:  A S Kemp; P Roberts-Thomson; S H Neoh; S Brown
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

9.  Leukotactic dystunction in sarcoidosis.

Authors:  E G Maderazo; P A Ward; C L Woronick; J Kubik; A C DeGraff
Journal:  Ann Intern Med       Date:  1976-04       Impact factor: 25.391

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  29 in total

Review 1.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 2.  The immunopathogenesis of Crohn's disease: a three-stage model.

Authors:  Gavin W Sewell; Daniel Jb Marks; Anthony W Segal
Journal:  Curr Opin Immunol       Date:  2009-08-08       Impact factor: 7.486

Review 3.  Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.

Authors:  J G Williams
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

Review 4.  Nutritional therapy in ambulatory patients.

Authors:  C A O'Morain
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

5.  Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome.

Authors:  Marjorie De la Fuente; Luigi Franchi; Daniela Araya; David Díaz-Jiménez; Mauricio Olivares; Manuel Álvarez-Lobos; Douglas Golenbock; María-Julieta González; Francisco López-Kostner; Rodrigo Quera; Gabriel Núñez; Roberto Vidal; Marcela A Hermoso
Journal:  Int J Med Microbiol       Date:  2014-02-06       Impact factor: 3.473

6.  In vivo assessment of granulocyte migration to diseased bowel in Crohn's disease.

Authors:  S H Saverymuttu; A M Peters; J P Lavender; V S Chadwick; H J Hodgson
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

7.  Acute colitis produced by chemotactic peptides in rats and mice.

Authors:  J F Chester; J S Ross; R A Malt; S A Weitzman
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

8.  Partial defect of neutrophil oxidative metabolism in Crohn's disease.

Authors:  H W Verspaget; M A Mieremet-Ooms; I T Weterman; A S Peña
Journal:  Gut       Date:  1984-08       Impact factor: 23.059

9.  Measurement of granulocyte migration and accumulation in inflammation in man.

Authors:  S H Saverymuttu; A M Peters; H J Reavy; J P Lavender
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

10.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease.

Authors:  Andrew M Smith; Farooq Z Rahman; Bu'Hussain Hayee; Simon J Graham; Daniel J B Marks; Gavin W Sewell; Christine D Palmer; Jonathan Wilde; Brian M J Foxwell; Israel S Gloger; Trevor Sweeting; Mark Marsh; Ann P Walker; Stuart L Bloom; Anthony W Segal
Journal:  J Exp Med       Date:  2009-08-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.